) and medical software developer OTTR (Organ Transplant Tracking
Record) Chronic Care Solutions have joined hands to integrate
their products and services to improve the workflows and
processes required to support organ, blood and marrow transplant
care delivery teams. However, the news failed to entice investors
as shares slid 0.7% following the announcement.
Currently, OTTR is the leading patient tracking application and
patient record system specifically tailored for solid organ
transplant centers and CERN will be the only electronic health
record provider to offer it. As a result, it will add significant
value to CERN clients and help clinicians to access real-time
data for better patient management and treatment decisions.
OTTR Chronic Care Solutions, operating since 1993, has contracts
with transplant centers in the U.S. and Canada. It supports more
than 200 different transplant programs till date.
Cerner reported adjusted net earnings of $128.1 million or 36
cents per share for the fourth quarter of 2013, topping the Zacks
Consensus Estimate of 34 cents per share. This reflected a 14.6%
rise from $111.8 million and 12.5% from 32 cents per share in the
comparable quarter a year ago.
However, reported net earnings fell 46.3% to $60.1 million from
$111.8 million in the fourth quarter of 2012 while earnings per
share dipped 46.9% to 17 cents from 32 cents per share in the
Revenues in the quarter grew roughly 12% to $795.3 million,
exceeding the Zacks Consensus Estimate of $793 million. Global
revenues went up 8% for the quarter. The increase can be
attributed to stronger revenues from Support, maintenance and
services and Reimbursed Travel, partially offset by weaker
revenues from System sales.
For the first quarter of 2014, CERN anticipates revenues between
$770 and $810 million while adjusted earnings are expected
between 33 and 34 cents per share, after share based compensation
expense. These compared with the Zacks Consensus Estimates of
$781 million 34 cents for revenues and earnings per,
respectively, for the quarter.
For full year 2014, CERN anticipates revenues in the range of
$3.2 to $3.4 billion. Adjusted earnings are expected between
$1.51 and $1.55, after share based compensation expense. These
compared with the Zacks Consensus Estimates of $3.3 billion and
$1.54 for revenues and earnings per share, respectively, for the
Currently, CERN retains a Zacks Rank #3 (Hold). Some
better-ranked stocks in the medical information sector include
Computer Programs & Systems Inc.
). Computer Programs & Systems and Omnicell sport a Zacks
Rank #1 (Strong Buy), while athenahealth carries a Zacks Rank #2
ATHENAHEALTH IN (ATHN): Free Stock Analysis
CERNER CORP (CERN): Free Stock Analysis
COMPUTER PRGRMS (CPSI): Free Stock Analysis
OMNICELL INC (OMCL): Free Stock Analysis
To read this article on Zacks.com click here.